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Abstract
Connective tissue growth factor (CTGF) is a signaling molecule that primarily functions in extracellular matrix maintenance
and repair. Increased Ctgf expression is associated with fibrosis in chronic organ injury. Studying the role of CTGF in fibrotic
disease in vivo, however, has been hampered by perinatal lethality of the Ctgf null mice as well as the limited scope of
previous mouse models of Ctgf overproduction. Here, we devised a new approach and engineered a single mutant mouse
strain where the endogenous Ctgf-39 untranslated region (39UTR) was replaced with a cassette containing two 39UTR
sequences arranged in tandem. The modified Ctgf allele uses a 39UTR from the mouse FBJ osteosarcoma oncogene (c-Fos)
and produces an unstable mRNA, resulting in 60% of normal Ctgf expression (Lo allele). Upon Cre-expression, excision of the
c-Fos-39UTR creates a transcript utilizing the more stable bovine growth hormone (bGH)3 9UTR, resulting in increased Ctgf
expression (Hi allele). Using the Ctgf Lo and Hi mutants, and crosses to a Ctgf knockout or Cre-expressing mice, we have
generated a series of strains with a 30-fold range of Ctgf expression. Mice with the lowest Ctgf expression, 30% of normal,
appear healthy, while a global nine-fold overexpression of Ctgf causes abnormalities, including developmental delay and
craniofacial defects, and embryonic death at E10-12. Overexpression of Ctgf by tamoxifen-inducible Cre in the postnatal life,
on the other hand, is compatible with life. The Ctgf Lo-Hi mutant mice should prove useful in further understanding the
function of CTGF in fibrotic diseases. Additionally, this method can be used for the production of mouse lines with
quantitative variations in other genes, particularly with genes that are broadly expressed, have distinct functions in different
tissues, or where altered gene expression is not compatible with normal development.
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Introduction
Many of the diseases that have a major impact on human health
and pose a major burden on healthcare costs have a fibrosis-
related component. Coronary heart disease (CHD) was the single
largest killer in the United States in 2003, accounting for 1 in every
5 deaths [1]. Forty percent of acute CHD incidents result in death,
but for those who survive an ischemic event, permanent scarring of
heart tissue is largely unavoidable. Both myocardial infraction (MI)
and chronic high blood pressure result in scarring of the
myocardium known as cardiac fibrosis [2]. Cardiac fibrosis is
characterized by necrosis of myocardial tissue, collagen buildup,
and scar tissue contraction often resulting in ventricular diastolic
dysfunction and a poor long term prognosis [3–5]. Similarly, both
diabetic nephropathy and cirrhosis of the liver have been identified
as diseases with a large burden on the healthcare system and are
characterized by fibrotic tissue damage [6,7]. Prevention of
cardiac fibrosis and fibrotic disease in other organs (kidney, liver,
lung and others) is a promising strategy of intervention for
improving long term prognosis and quality of life.
All of the fibrosis-related diseases mentioned are characterized
by overexpression of connective tissue growth factor (CTGF
or CCN2, ENSMUSG00000019997), a primary fibrosis-related
signaling molecule [8]. CTGF is a member of the CCN (Cyr61,
Ctgf, and Nov) family of extracellular matrix (ECM) associated
proteins. Ctgf is widely expressed during development, and in
adulthood it is expressed in all major organs including the
vasculature and the skeletal system [9,10]. In the adult, expression
is nearly ubiquitous and promotes normal turnover and mainte-
nance of ECM. As part of normal wound healing following injury,
there is a marked induction of Ctgf expression [11]. Essentially,
CTGF acts as a central coordinator of multiple pro- and anti-
fibrotic signals and misregulation of CTGF is believed to result in
tissue fibrosis and scarring [11,12]. Increased Ctgf expression is
clearly associated with fibrosis in multiple tissues including skin,
liver, heart, lung, and kidney (reviewed in [11,12]). In addition,
CTGF is a diffusible protein and can be detected in urine and
blood [13,14]. A critical difference between healthy healing and
pathological fibrosis may be the temporal regulation of, and/or the
level and duration of, Ctgf expression. Thus, it is postulated that
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tissues and induce healthy, non-fibrotic healing [15].
To examine the role of CTGF in vivo, several animal models
have been created. The first is a traditional knockout, which when
homozygous, is perinatally lethal. The pups are born, but do not
survive due to skeletal deformity, including a malformed rib cage
which causes an inability of pups to breathe properly. The
heterozygous knockouts survive and have little discernable fibrosis-
related phenotype [16]. Transgenic models of Ctgf overproduction
in bone and cartilage, cardiomyocytes, kidney podocytes, hepato-
cytes, lung epithelia and fibroblasts have also been made using
promoter-enhancers constructs specific to each cell type [17–23].
The fibrotic phenotypes of these strains vary widely ranging from
no increase in fibrosis to a clear fibrotic phenotype. In all of these
models the relationship between gene expression level and
phenotype is not clear since the normal control of Ctgf gene
expression is disrupted and the mechanism by which altered steady
state Ctgf gene expression influences non-target tissues has not
been described. Thus, the role of Ctgf expression in fibrosis remains
unclear and there is a need for animal models with variable Ctgf
expression in which there is minimal alteration in the natural
transcriptional regulation to clarify how altered Ctgf expression
levels may predispose or change the progression of heart disease
and other fibrotic diseases.
Here we describe an innovative method of modulating gene
expression by making one animal that can express either low
or high levels of a gene. This is made possible by use of Cre-
recombinase to alter expression in vivo from low to high. The
endogenous 39-untranslated region (39UTR) is replaced with a
cassette containing the 39UTR from the FBJ osteosarcoma
oncogene (c-Fos, ENSMUSG00000021250) and the 39UTR from
the bovine growth hormone (bGH) gene, also known as somato-
tropin (ENSBTAG00000017220), placed in tandem. Each 39UTR
modulates the stability of the mRNA transcript and can
respectively decrease (c-Fos) or increase (bGH) steady state levels
of mRNA in both cells and whole animals [24–27].
Using this method, we have created a single construct that
allows the examination of the role of Ctgf when it has reduced
expression, increased expression, or when expression is altered in a
tissue-specific manner. Our results show that Ctgf expression
reduced to 30% of wild type is survivable, while expression nine
fold higher than wild type leads to embryonic lethality by day
E12.5. Thus, we have created a 30-fold range of Ctgf expression in
vivo, which should prove useful in further understanding the
function of CTGF in fibrotic disease.
Results
Global, conventional KO of the Ctgf gene
In order to inactivate the Ctgf gene, we have made a targeting
construct to delete exons 3 through 5 of the Ctgf gene in the
genome in ES cells as illustrated in Fig. 1A. The 59 and 39 arms of
homology are a 4.7 kb BamH1/Nhe1 fragment and a 1.4 kb
Nsi1/Bgl2 fragment, respectively. A neomycin resistant gene was
used as a selection marker. Mice heterozygous for an inactivated
Ctgf KO allele appear normal and express the Ctgf gene at
approximately 50% levels. As reported by Ivkovic et al,
homozygous mice completely lacking CTGF are born but die
within 16 hours [16].
Strategy to generate the Ctgf-Lo and Ctgf-Hi alleles
Our initial attempts to increase the stability of Ctgf transcripts in
vivo using 39UTR replacement with the bGH-39UTR [24] met
with difficulties. Chimeric mice with a modified allele tended to be
runted and did not transmit the modified allele (data not shown).
In order to circumvent the potential embryonic lethality of high
Ctgf expression and generate adult mice overexpressing the Ctgf
gene, we devised a novel strategy using a low-high cassette (Lo-Hi)
that allows us to change gene expression levels from low to high by
altering mRNA stability (Fig. 1B). The second line in Fig. 1B
illustrates the Ctgf-Lo allele made by a replacement of the endo-
genous Ctgf gene 39UTR sequence with a cassette that includes
a loxP site, followed by the 39UTR sequence from the FBJ
osteosarcoma oncogene (c-Fos-39UTR), the neomycin resistant
gene (neo), a second lox P site, and the bGH-39UTR. The modified
allele, Ctgf-Lo, uses the c-Fos-39UTR and so its transcripts are less
stable than those from the wild type Ctgf allele. However, a Cre-
mediated recombination between the two loxP sequences in the
Lo-Hi cassette excises the c-Fos-39UTR and the neo gene and
generates the Ctgf-Hi allele that uses bGH-39UTR (Figure 1B, third
line). The transcript with the bGH-39UTR is more stable than nor-
mal and consequently steady state levels of Ctgf mRNA increase.
Mice with low Ctgf expression
Heterozygotes for the Ctgf-Lo (Ctgf Lo/+) allele are born and
appear normal. Ctgf Lo/+ mice were first intercrossed to determine
if the Ctgf Lo/Lo phenotype is viable. Pups were born from this
cross at a 10:18:5 genotypic ratio (+/+: Lo/+: Lo/Lo). The number
of Ctgf Lo/Lo pups was about half the expected Mendelian ratio
of 1:2:1 for the cross, but the Chi square test was not significant
(p=0.409, n=33). The Ctgf Lo/+ and Ctgf Lo/Lo pups are healthy,
reproduce normally, and are indistinguishable from their wild type
and heterozygous littermates.
The Ctgf Lo/Lo mice are expected to have reduced Ctgf mRNA
expression throughout the body. Tail snips from 10 day old pups
were used to assay for Ctgf mRNA expression. Ctgf Lo/Lo mice
express about 60% of wild type levels of Ctgf. The Ctgf Lo/Lo mice
are similar in Ctgf expression level to the Ctgf heterozygous
knockout (Ctgf KO/+) mice which express 50% of wild type Ctgf.
Ctgf Lo/+ heterozygotes have an intermediate Ctgf expression level
that is 85% of wild type mice (+/+: 100%66.8, n=21, Lo/+:
85%65.1, n=25, p,0.05, Lo/Lo: 60%611.4, n=5, p,0.005,
Figure 2A).
Mice with very low Ctgf expression
Ctgf Lo/Lo mice were crossed to Ctgf heterozygous knockouts
(Ctgf KO/+) to generate mice with very low Ctgf expression (Ctgf Lo/
KO). Ctgf Lo/KO mice were born at the expected Mendelian ratio
of 1:1 (17 Lo/+:1 5Lo/KO). Tissues from adult siblings (males and
females) were assayed for Ctgf mRNA expression by RT-PCR. Ctgf
Lo/KO heart tissue had significantly lower Ctgf expression (heart:
Lo/KO: 30%64.2, n=7, Lo/+: 85%614.3 for, n=14, p=0.002,
Figure 2B). Similarly, both kidney and lung had significantly
reduced Ctgf expression (kidney: Lo/KO: 33%623.5, n=8, Lo/+:
85%615.0, n=14, p=0.01 and lung: Lo/KO: 23%611.9, n=8,
Lo/+: 85%627.9, n=14, p=0.02, Figure 2B). When the results
from various tissues are combined, Ctgf expression in Lo/KO mice
is on average 29% of wild type ((30%+33%+23%)/3=28.7%).
The Ctgf Lo/KO animals reproduce adequately, are healthy,
phenotypically normal in appearance, and display no overt
structural phenotypes.
Embryonic lethality in mice with high Ctgf expression on
a B6.129 mixed background
When Cre is present, a Cre-mediated recombination between
the two loxP sequences within the Ctgf-Lo allele excises the c-Fos-
39UTR and the neo gene, this generates the Ctgf-Hi allele that uses
Ctgf Gene Expression Variants
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Lo/+ mice on a B6.129 mixed genetic background were crossed to
a heterozygous whole body Cre expressing mouse line
129.Tg(Ella-Cre) (from B6.FVB-Tg(EIIa-cre) C5379Lmgd/J stock
that was backcrossed to 129/SvEv for 18 or more generations).
Heterozygotes for the Ctgf Hi allele (Ctgf Hi/+ mice) were defined
as presence of the bGH-39UTR, presence of a Cre allele and low
Neo gene copy number. After seven litters and 40 pups, no live
mice carrying both the modified Ctgf allele and the EIIa-Cre
transgene were recovered, suggesting the Ctgf-Hi allele causes an
embryonic lethal phenotype.
To examine the timing and nature of the lethality, we used
timed matings and recovered embryos between E13.5 and E14.5.
At this embryonic age, Ctgf Hi/+ embryos were recovered at a
ratio of 10:15:11:7 (+/+;Cre-: Lo/+;Cre-: +/+;Cre
+: Hi/+;Cre
+)
which was not different from the expected Mendelian genotypic
ratio of 1:1:1:1 (Chi Square, p=0.385, n=43).
At recovery, embryos were weighed and phenotypically classified
as normal, small, or small atyical without knowledge of the
genotype. Normal embryos were nondysmorphic in appearance,
of the expected developmental stage for the embryonic age, and
were within two standard deviations of the mean embryo weight for
that litter. Small embryos were nondysmorphic in appearance and
of the expected developmental stage for the embryonic age, but
small in size with a body weight below two standard deviations of
the litter average (litter averages include all pups that were
sufficiently intact to be weighed). Small atypical embryos were
developmentally delayed, macerated, or poorly vascularized with a
body weight below two standard deviations of the litter average. By
this classification method, no normal Ctgf Hi/+ embryos were
present among 43 embryos at E13.5-E14.5 (Figure 3). All of the Ctgf
Hi/+ embryos were either small or small atypical and were similar
in appearance to the examples in Figure 4E, which would be
classified as small atypical (Fig. 4A is a normal embryo from the
same litter). In addition to small size and weight, the Ctgf Hi/+
embryos generally lacked clearly visible vasculature, lagged behind
in development, and many were macerated and likely to be in the
process of reabsorption (Figure 4E). This suggests that the embryos
begin to die before E13.5. While the reason for the lethality is
unclear, we observed a less developed eye (4e top arrow), as a mark
of developmental delay and craniofacial defects including both
lateral and midline facial clefting (4e middle and bottom arrow,
respectively). No Ctgf Hi/+ embryos were recovered from the litters
older than embryonic day point 14.5.
Figure 1. Ctgf KO and Ctgf Lo-Hi allele. A) Ctgf KO allele. Line 1 is the endogenous Ctgf locus. Line 2 is the Ctgf KO allele construct. Line 3 is the
result following homologous recombination where exons 3–5 of the Ctgf gene were replaced with a neo cassette to generate the Ctgf KO allele. Black
boxes indicate coding exons and a white box indicates the endogenous 39UTR. B) Ctgf Lo-Hi allele. Line 1 is the endogenous Ctgf locus. The Ctgf Lo-Hi
allele was generated by replacement of the endogenous Ctgf-39UTR with a construct containing the c-fos-39UTR and a Neo cassette flanked by loxP
sites, followed by the bGH-39UTR. In line 2, the modified Ctgf gene uses the less stable c-Fos-39UTR which reduces gene expression (Ctgf Lo allele). In
the bottom line, following Cre-mediated recombination, the c-Fos-39UTR and Neo cassette are excised and the Ctgf gene uses the more stable bGH-
39UTR which increases gene expression (Ctgf Hi allele). TAA indicates a stop codon Restrcition sites are abbreviated B is BamH1, Bc is Bcl1, Nhe is
Nhe1, Nsi is Nsi1, and Bg is Bgl2.
doi:10.1371/journal.pone.0012909.g001
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a 129/SvEv background
In order to investigate the timing of the lethality more closely
and to examine embryo viability in a pure 129/SvEv background,
Ctgf Lo/Lo mice on a 129/SvEv background were crossed with
129.Tg(Ella-Cre) mice. After genotyping three litters, no Ctgf Hi/+
embryos were recovered at E13.5, suggesting an earlier lethality in
the fully inbred background. Embryos on a 129/SvEv background
were then harvested at E10.5 (Figure 4 B-D and F-H) for
examination of morphology.
Figure 2. Ctgf mRNA levels by quantitative RT-PCR. A) Ctgf mRNA expression from tail samples of 10 day pups from a cross of Ctgf Lo/+ parents.
All mice are siblings. The mean of Ctgf +/+ (wild type) expression is set to 100% expression LoLo:n=5 ,Lo/+: n=25, and +/+: n=21. B) Ctgf mRNA
expression from tissues of five month old mice. Ctgf Lo/+ mice are the control with Lo/+ expression set to 85% based on results from Figure 2A. For
each organ Lo/+: n=14 and Lo/KO:n=8 .C )Ctgf mRNA expression from whole mouse embryos at day points E11.5, normalized to Lo/+ the same as
Figure 2B. Lo/+: n=8 and Hi/+:n=1 3D )Ctgf mRNA expression from tissues of 10 month old mouse tissues normalized to a combined control of
animals of the genotypes +/+;Cre-, Lo/+;Cre-, and +/+;Cre
+. E) Neo gene copy number in embryos at day E11.5. Copy number is in arbitrary units and
normalized to Lo/+=100%. Lo/+: n=18 and Hi/+: n=28. For all graphs the Lo/+ animals are heterozygous for the Ctgf Lo allele and do not have a Cre
allele. The Hi/+ animals are heterozygous for the Ctgf Hi allele and have one EIIa-Cre allele.
doi:10.1371/journal.pone.0012909.g002
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and a number of morphological defects. The gapping open mouth
posture seen in Figure 4F (bottom arrow) and 4G is suggestive of a
small forebrain (also 4B and 4F top arrow) and the abnormal
indentation of the back of the head seen in Figure 4G (bottom
arrow) suggests an abnormal hindbrain. The embryo in Figure 4G
also appears to have less visible microvasculature in the face and
possibly elsewhere and has a less developed eye (top arrow 4 g)
suggesting possible developmental delay. Additionally, the closure
of the pharyngeal (branchial) arches, particularly between the first
and second (pharyngeal cleft one) and second and third arch
(pharyngeal cleft two), were abnormally patent (compare Figure 4D
to 4H).
No Ctgf Hi/+ embryos on a 129/SvEv inbred background were
recovered beyond E12.5 suggesting the lethality on the 129/SvEv
background is earlier than that of the B6.129 background, at
around day E11.5-E12. Despite the earlier time point of lethality
in the 129/SvEv background, developmental delay and craniofa-
cial defects were present in both backgrounds.
Gene expression levels of Ctgf Hi/+ embryos
In order to examine the expression levels of the Ctgf-Hi allele,
Ctgf Lo/Lo females were crossed to 129.Tg(Ella-Cre) Cre
+ males
and the embryos were harvested at E11.5 and assayed for whole
body Ctgf gene expression using RT-PCR. Ctgf expression varied
greatly in Ctgf Hi/+ embryos, ranging between two and fifty times
greater than the mean of Ctgf Lo/+ embryos. Most likely this is due
to variations in developmental stage, embryo condition, and
variations in Cre expression. On average the Ctgf Hi/+ embryos
had a greater than ten fold increase in Ctgf mRNA levels compared
to the Ctgf Lo/+ littermate controls, which is a nine fold increase in
Ctgf expression over WT (Lo/+: 85%634, n=8 and Hi/+:
930%6506, n=13, p,0.05, Figure 2C).
To validate that excision of the c-fos-39UTR and neo gene was
occurring, whole embryos were assayed for neo gene copy number
as a measure of excision efficiency. On average Ctgf Hi/+ embryos
had less than one eighth the amount of neo alleles than the Ctgf Lo/
+ embryos (Lo/+: 100%67.8, n=18 and Hi/+: 11.6%61.7,
n=28,p,1610
27,F i gu re2 E) .Wh il eth eex c i si onofthec-fos-39UTR
and neo is not complete, the switch from the Lo alleletotheHi allele is
occurring efficiently and in the large majority of cells. There did not
appear to be a direct relationship between reduction in neo copy
number and increase in Ctgf gene expression levels suggesting that
mechanisms other than just efficiency of c-fos-39UTR and neo
excision were regulating Ctgf gene expression levels in the embryos
(data not shown).
Pattern of CTGF protein in embryos
Increased Ctgf mRNA levels may be causing changes in the
levels or pattern of CTGF protein in Ctgf Hi/+ embryos. Thin
sections of embryos were stained with a CTGF antibody and a
fluorescent seconday then counterstained with DAPI to visualize
the level and pattern of CTGF protein. CTGF was visible in
almost evey tissue of the embryos and appeared to be primarily
staining the extracellular matrix and the cell surface (Fig. 5I–5L).
The Hi/+ embryo in Fig. 5D has the highest CTGF staining and
the Lo/+ embryo in Fig. 5A the lowest staining, suggesting a
genotype dependent difference CTGF levels. Although the heart
in Fig. 5A is staining strongly, this likely represents a specific and
perhaps short-lived induction of CTGF in the heart during em-
bryogenesis. The other two embryos (Fig. 5B and 5C) have similar
staining intensity despite being different genotypes suggesting
CTGF levels vary substantially within each genotype. For the most
part individual differences in staining were greater than the dif-
ferences between genotypes, and there was not a distinct difference
in the pattern of CTGF staining nor a dramatic difference in the
overall intensity of CTGF staining between Ctgf Lo/+ and Ctgf Hi/+
(Figure 5). Immunohistochemistry (IHC) with a higher antibody
concentration and E13.5 mixed genetic background embryos
yielded a similar result (data not shown).
Survivors with high Ctgf gene expression
After many matings, four Ctgf Hi/+ animals (out of 81 that were
genotyped) escaped embryonic lethality and survived to adulthood
(26:28:23:4 ratio of +/+,Cre2: Lo/+,Cre2: +/+,Cre
+: Hi/+,Cre
+).
One male and one female of the surviving animals were siblings
from a mixed B6.129 mating. Two additional male survivors came
one year later, one from a mixed B6.129 mating and one from a
129/SvEv mating. All four mice exhibited the same phenotype: a
shortened face, small ears, a shortened and kinked or curled tail,
and a shortened overall body length (Figure 6).
The surviving Ctgf Hi/+ animals and their sibling controls were
further characterized by dual energy x-ray absorptiometry (DEXA)
to assess whole body: bone mineral density (BMD), bone mineral
content (BMC) and body composition (lean, fat and % fat mass).
Although the number of samples was small and the animals were in
different genetic backgrounds, all of the Ctgf Hi/+ animals had
significantly smaller bone area and lean mass than controls (bone
area: controls: 9.8760.33 cm
2 and survivors: 8.3560.57 cm
2;l e a n
mass: controls: 25.461.1 grams and survivors: 21.060.95 grams,
controls: n=9 and survivors: n=4, p,0.05, Table 1) indicating a
smaller overall body size as suggested by their outward appearance.
The BMC of Ctgf Hi/+ survivors was low suggesting changes in the
bone mineralization or morphology (controls: 0.64260.033 grams,
n=9 and survivors: 0.53260.052 grams, n=4, p,0.05, Table 1).
At sacrifice several tissues including fat pads were collected and
weighed to determine any gross differences. There were no
differences in total amount or relative amounts of renal, inguinal,
or mesenteric fat (data not shown). Organ weights tended to be
smaller with both kidney and lung significantly smaller in the Ctgf
Hi/+ survivors (Kidney: controls: 0.22160.010 grams and
survivors: 0.17060.013 grams; Lung: controls: 0.13360.009
grams and survivors: 0.09760.008 grams, controls n=9 and
Figure 3. Phenotype of E13.5 embryos. Embryos are from a cross
between Ctgf Lo/+ and EIIa-Cre +/- parents. The number of embryos for
each genotype classified as Normal, Small, or Small atypical. +/+ n=9,
Lo/+ n=15, Cre
+ n=11, Hi/+ n=7. The +/+ animals are wild type for Ctgf
and do not have a Cre allele, Lo/+ animals are heterozygous for the Ctgf
Lo allele and do not have a Cre allele. Cre
+ are wild type for Ctgf and
have one Cre allele. And Hi/+ are heterozygous for the Ctgf Hi allele and
have one Cre allele.
doi:10.1371/journal.pone.0012909.g003
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ratio of total body weight tended to be smaller in Ctgf Hi/+
survivors but were not significantly different from the controls
(Table 1). The organ weight ratios were not different from controls
because at sacrifice the Ctgf Hi/+ survivors were smaller in total
body weight than controls (controls: 35.72061.65 grams, n=9
and survivors: 29.05763.57 grams, n=4, p,0.05, Table 1)
suggesting that Ctgf Hi/+ survivors have a normally proportioned
but smaller body size.
Heart, kidney and lungs from Ctgf Hi/+ survivors and siblings or
age-matched controls were harvested and assayed for Ctgf gene
expression using RT-PCR. There was a significant increase in Ctgf
expression in each tissue (Figure 2D). The heart had a modest
increase at two-fold above controls, kidney is three-fold increased,
and lung had the largest change at nearly five-fold increased Ctgf
expression over sibling controls (Heart: Lo/+: 85%69.6, Hi/+:
190%616.6, p,0.0001; Kidney: Lo/+: 85%611.6, Hi/+: 286%6
67.9, p,0.001; Lung: Lo/+: 85%610.1, Hi/+: 482%6111.6,
p,0.0001, n=9 controls and n=4 survivors, Figure 2D). At the
time of sacrifice, 10 months of age, the Ctgf Hi/+ survivors
appeared healthy and did not seem to have accelerated aging.
Histological evaluation of sections of heart, kidney, and lung was
not remarkable and not different from age matched controls (data
not shown).
Global increase of Ctgf gene expression in adult mice
The survival of several animals with very high Ctgf expression
suggests that while high Ctgf expression is embryonic lethal, in
an adult it is compatible with survival. To test this hypothesis
we crossed Ctgf Lo/Lo mice with CAG-Cre mice, which are a
tamoxifen-inducible global Cre expresser strain [28]. At four to six
weeks of age, offspring were treated with tamoxifen to induce Cre
expression. PCR of small skin biopsy of tamoxifen-treated animals
showed that the Lo-Hi allele functioned as predicted with excision
of the c-fos-3-UTR and neo (Lo allele) to generate the smaller the
Hi allele in the presence of tamoxifen and the inducible Cre gene
(Figure 7C). Similar to Hi/+ survivors and embryos, Ctgf gene
expression in Cre expressing mice (Ctgf Hi/+ mice, after tamoxifen
treatment) was approximately four-fold higher than in Ctgf Lo/+
mice without the Cre gene (Lo/+: 85%615.3, n=23 and Hi/+:
357%663.4, n=20, p.0.00005, Figure 7A).
Three months after tamoxifen treatment both males and
females remained indistinguishable from the non-Cre carrying
littermates, suggesting that high levels of Ctgf expression in the
adult are survivable. This experiment also shows that our construct
can be used in an inducible fashion to study fibrotic disease in
adult animals.
CTGF protein levels in plasma
To confirm that changes in Ctgf mRNA expression translated to
changes in CTGF protein abundance, a Western blot of plasma
samples with a mouse-specific CTGF antibody was performed for
quantitation. CTGF is a secreted protein and is known to circulate
in plasma at measurable levels. Recent human and mouse research
has suggested that CTGF protein levels in the plasma can be used
as a non-invasive marker of Ctgf gene expression levels [29,30].
Band sizes ranging from 11 kDa to the full length 38 kDa have
been reported in Western blots for CTGF, including multiple
reports of a doublet around 31 kDa [31,32]. The primary band we
observed for CTGF in adult plasma was a doublet around 31 kDa
(Fig. 7D). Quantitation by densitometry showed that the Ctgf Lo/Lo
mice had significantly reduced CTGF protein to a level that was
about 60% of wild type (Lo/Lo: 0.6260.077, n=5, +/+:
1.0060.135, n=5, p,0.05, Figure 7B), which is similar to the
Ctgf Lo/Lo mRNA expression levels (Figure 2A). In contrast,
tamoxifen-treated Ctgf Hi/+ animals had significantly increased
CTGF protein abundance of about 170% of wild type (Hi/+:
1.7260.037, n=7, p,0.0001, Figure 7B). While this is not as high
as the mRNA expression levels it is a significant and very
consistent increase in CTGF protein levels.
Discussion
Previous studies have shown that altering or interchanging
the 39UTR of a gene is an effective method for altering gene
expression in cells and in animals [24–27]. The method takes
advantage of the idea that the 39UTR, in part, regulates mRNA
abundance primarily through modulating mRNA stability. In
altering the stability of a gene’s mRNA, the mRNA abundance
and thus the protein abundance can be modulated in a
qualitatively predictable manner. By combining Cre-lox technol-
ogy with the use of two well-characterized 39UTR sequences, c-
Fos-39UTR and bGH-39UTR, a single allele that can decrease or
increase gene expression has been assembled. This method was
applied to the gene Ctgf to generate an allelic series that has a 30-
fold range of Ctgf expression as summarized in Table 2. In
addition, in line with previous reports by Ivkovic et al [16], our Ctgf
KO/KO (homozygous knockout) are born but die within a day.
We found that embryos with a Ctgf Hi allele had increased Ctgf
mRNA levels that were nine-fold higher than WT in embryos and
the increase in Ctgf expression was embryonic lethal, depending on
genetic background, between day E11 and E13.5. The lethality of
the Ctgf Hi allele, made from the Lo-Hi allele, recapitulates the
lethality observed in our previous attempts to directly generate a
Ctgf Hi allele with the bGH-39UTR. Embryos from both 129/SvEv
and B6.129 mixed backgrounds display craniofacial defects
consistent with alterations to the first and second pharyngeal
arches. The fissures between the arches in the mutant E10.5
embryo in Figure 4H do not have a jagged border or other
morphology that indicates a handling-related tear. In addition,
similar fissures were observed in two other Ctgf Hi/+ embryos,
suggesting that this defect was a result of high Ctgf gene expression.
Defect of the pharyngeal arches, rostrum and midline in Ctgf Hi/+
embryos are in congruence with previous reports that Ctgf is highly
expressed in these regions at E9.5-E10.5 [16]. In humans, altered
development of the first and second pharyngeal arches is known to
cause malformations of the ear, cheekbone, upper and lower jaw,
soft palate, eye, and facial muscles and nerves [33]. In particular,
Figure 4. E14.5 and E10.5 embryos. A) and E) are fixed embryos at E14.5 from a cross between Ctgf Lo/+ and EIIa-Cre +/2 B6.129 mixed
background parents. A) is a normal Lo/+ and E) is a small atypical Hi/+ at higher magnification. Top arrow denotes less developed eye in E) and the
lower two arrows point to lateral and midline facial clefting, respectively. Embryos B) to D) and F) to H) are E10.5 embryos from a cross between Ctgf
Lo/Lo and EIIa-Cre +/2 129/SvEv background parents. B), C), and F), G), are unfixed embryos. B), C) and D) are normal Ctgf Lo/+ embryos. F), G), and H)
are Ctgf Hi/+ embryos. The top arrow in B) and F) points to the forebrain which appears smaller in F) and the lower arrow points to the mouth gape in
F) also indicative of a small forebrain. The top arrow in C) and G) points to the eye and the bottom arrow points to the hindbrain which both appears
abnormal in G). The pictures in D) and H) are from scanning electron microscopy. The arrows in D) and H) point to the first (top) and second (bottom)
pharangeal (branchial) clefts. In D) there is normal closure of the clefts and in H) the clefts are abnormally patent (open). B) and C) are the same
embryo and F) to H) are the same embryo. The bars in A), B), E), and F) represent 1000 mm and in C), D), G), and H) the bars represent 250 mm.
doi:10.1371/journal.pone.0012909.g004
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between the arches) are associated with oblique or lateral clefting
and cervical/branchial (neck) fistula [34].
The generalized developmental delay and craniofacial defects
like those seen in Ctgf Hi/+ embryos by themselves are not
necessarily lethal [35], so it remains unclear why the Ctgf Hi allele
is embryonic lethal. Craniofacial defects are often observed in
conjuction with cardiac defects and both phenotypes are thought
to be caused by improper migration and differentiation of neural
crest cells [36,37]. Defects including craniofacial dysmorphism and
abnormal pharyngeal arches as well as cardiac defects were
observed in transforming growth factor (TGFb) family knockout
mutant mouse strains and were thought to be caused by defective
neural crest cell migration [36]. Although, TGFb isoforms are
most commonly thought to increase Ctgf expression [38], there are
recent reports that suggest Tgfb2 can inhibit Ctgf expression [39]. If
TGFb2 is regulating CTGF in utero, loss of Tgfb2 could lead to
increased levels of CTGF, creating a similar phenotype to our
model of increased Ctgf expression. Therefore, dysfunction of
neural crest cells, which likely causes the craniofacial defects in Ctgf
Hi/+ embryos, may be the ultimate reason for the embryonic
lethality. No overt defects were observed in the heart in our limited
histological analysis, and immunohistochemical staining revealed
that Ctgf expression may be generally increased in Hi/+ embryos
but is not consistent. Despite the large increase in mRNA,
immunohistochemistry (IHC) does not show large differences in
CTGF levels suggesting that IHC may not be sufficiently sensitive
or that translational regulation may be occurring. Future experi-
ments using in situ hybridization and/or tissue-specific over-
expression of Ctgf should focus on defects in neural crest cells,
Figure 5. Immunofluorescence of E11.5 Ctgf Lo and Hi embryos. Panels A) – D) are stained with an anti-CTGF antibody and a Alexa 594 (Texas
Red) secondary. Panels E) – H) are stained with DAPI to highlight nuclei. Panels I) – L) are a merge of the Red and the DAPI layer. Genotypes for each
panel are as marked on the panel. The panels in each row are from the same section. All panels are at 56magnification.
doi:10.1371/journal.pone.0012909.g005
Figure 6. Survivors of Ctgf Hi/+ embryonic lethality. Gross morphology of high Ctgf-expressing survivors at 10 months old. Males are shown in
A) and B) and females are shown in C) and D). In A) and B) the Ctgf Hi/+ mice (foreground) have small ears, shortened face and short body length. B)
The short curly tail of the Hi/+ male. D) Short kinked tail and short body of the Hi/+ female (top) compared with a control sibling (bottom). All the
animals shown are siblings from a cross between Ctgf Lo/+ and EIIa-Cre +/2 animals on a mixed B6.129 background. The controls (background of A)
and C) and bottom of D)) are of the genotype Ctgf Lo/+.
doi:10.1371/journal.pone.0012909.g006
Ctgf Gene Expression Variants
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12909especially in the heart, as a possible cause for the Ctgf Hi/+
embryonic lethality.
Alternative causes for lethality in Ctgf Hi/+ embryos include
failures of vasculogeneis or erythropoeisis, both are crucial devel-
opmental milestones of E10-E12 embryos [40]. Many of the Ctgf
Hi/+ embryos recovered appeared generally pale and may have
lacked proper circulation. Vascular endothelial growth factor
(VEGF) is known to be an essential factor in vasculogenesis and is
thought to have a complex regulatory relationship with CTGF
[41–43]. Disruption of VEGF signaling caused by high CTGF
levels could be the cause of this defect. Failures in placental
development, cell migration, or hematopoietic proliferation at this
embryonic stage are also common reasons for embryonic lethality
andcould bethe causeoflethalityintheCtgfHi/+embryos[44–46].
An unexpected benefit of the uneven penetrance of the EIIa-Cre
has been the few animals that have escaped the embryonic lethality.
Genotyping showed that the survivors do not have complete neo
excision in tail DNA suggesting they are mosaics for the Ctgf Lo and
Ctgf Hi alleles and likely escaped lethality due to low Cre expression
during embryogenesis. Like the embryos, the survivors express
significantly increased Ctgf as well as exhibit craniofacial defects in
the form of a shortened rostrum. In addition, similar to previously
reported Ctgf high expression transgenics, [17,18] the survivors have
skeletal defects in the form of shorted body-length, shortened or
kinked tails, and reduced bone mineral content. All of these
similarities as well as mRNA expression levels suggest that the Ctgf
Hi/+ survivors are true high expressers.
The EIIa-Cre line is known to have a mosaic pattern of Cre
expression with varying excision efficiency in different tissues as
well as large variability between animals in the amount of
Cre-mediated excision. Previous reports have shown that with
the Ella-Cre as few as 50% of animals undergo high levels of
Cre-mediated excision in the first generation [47,48]. The EIIa-
Cre expression profile reported by The Jackson Laboratory shows
that certain organs such as lung and kidney have very high Cre
expression in adults and other organs such as heart have much
lower Cre expression [49]. It is noteworthy that the pattern of gene
expression observed in our survivor mice is similar to the report of
Cre expression by The Jackson Laboratory and shows that Ctgf
expression is moderately increased in heart (two-fold) and
substantially increased in the kidney and lung (three-fold and
five-fold, respectively).
These surviving animals are rare with only four animals
surviving the embryonic lethality in two years of breeding.
Matings of survivor males never produced offspring that carried
a fully floxed (neo negative) high expressing allele, reinforcing that
the Ctgf Hi/+ allele is embryonic lethal. Therefore, due to their
rarity and lack of direct transmission of the Ctgf Hi/+ allele, these
animals are not a tenable model for Ctgf overexpression.
We then used a mouse strain that expresses tamoxifen-inducible
Cre gene and showed that high Ctgf expression in an adult is not
lethal. With only a moderate dose of tamoxifen, these animals
express a four-fold increase in Ctgf mRNA and a nearly two fold
increase in CTGF protein abundance in plasma and do no appear
to suffer any immediate ill effects. Unlike the low Ctgf expression
models where decreases in protein levels paralleled that of mRNA,
in the Ctgf Hi/+ there is a two-fold difference between the protein
abundance in plasma (1.7-fold increased) and the tissue mRNA
gene expression (3.6-fold increased). The discrepancy may be due
to the inaccuracy of the method used to quatitate the protein or to
unknown regulation at the translational level. The increase in Ctgf
mRNA was not as high as in the embryos so a higher tamoxifen
dose, or treatment at a younger age, may increase Ctgf expression
to a level closer to the nine-fold increase we observe in embryos.
Previous reports have implicated CTGF as a profibrotic signaling
molecule leading to the suggestion that reducing Ctgf expression by
treatment with a drug or a monoclonal antibody may be a worth-
while therapeutic strategy in treating fibrotic disease [11,29,30].
This therapeutic strategy, however, remains largely untested. The
lack of overt fibrotic phenotype in histological analysis of the Ctgf
Hi/+ survivors and the externally normal phenotype of the
tamoxifen treated Ctgf Hi/+ animals suggests that genetically
increasing Ctgf expression by itself is not sufficient to cause fibrosis.
This is consistent with a report which showed that exogenous
application of CTGF to the skin alone is not sufficient to cause
fibrosis[50].TransgenicmiceoverexpressingCtgfincardiomyocytes
[19], kidney podocytes [20], and hepatocytes [21] show no
spontaneous fibrosis of tissue while transgenic mice overexpressing
Ctgfinlungrespiratoryepithelialcells[22],andfibroblasts[23]show
abnormal thickening of the alveolar septa or dermis and fibrotic
alterations [22,23]. However, fibrosis in the lung-specific model is a
largely development-related phenotype [22] and in the fibroblast-
specific model the in vivo level of Ctfg expression was not established
[23], so these results may differ from ours because of differences in
levels of Ctgf expression or that the transgene is not responsive to
normaltranscriptionalregulationoftheCtgfalleleatthe endogenous
locus. Altogether, the current literature does not preclude a role for
CTGF in fibrotic disease, but it suggests that activation of other
factors or the application of stress may be required in addition to
Ctgf overexpression in order to cause fibrosis.
Increased Ctgf expression has been observed in conjunction with
fibrotic pathology in a number of organs and disease conditions.
However, an unequivocal role for Ctgf as a causal factor in
pathological fibrosis remains questionable. An allelic series with a
wide range of genetically altered Ctgf gene expression provides a
tool to test, the effectiveness of reducing Ctgf expression, in vivo,t o
Table 1. DEXA and necropsy measurements of Ctgf Hi/+
survivors and sibling controls.
Measurement Control Hi/+;C r e+
T-Test p-
value
Bone (DEXA) BMD (g/cm
2) 0.0648 0.0635 0.357
BMC (grams) 0.642 0.532 0.048
Area (cm
2) 9.87 8.35 0.016
Tissue (DEXA) Lean (grams) 25.4 21.0 0.013
Fat (grams) 11.3 9.9 0.312
Total (grams) 36.7 30.8 0.072
% Fat 30.0 30.0 0.485
Weight (Fresh) Total 35.720 29.057 0.037
Kidney 0.221 0.170 0.007
Heart 0.167 0.142 0.081
Lung 0.133 0.097 0.017
% of Body Weight Heart/Total 0.475 0.485 0.347
Kidney/Total 0.311 0.300 0.329
Lung/Total 0.381 0.343 0.268
The top half of table is DEXA measurements of live mice at 10 months of age
and the bottom is necropsy data. Mice were euthanized at 10 months of age
and total body weight and organ weights were measured. Males and females
were pooled. The p-value for each measurement is from Student T-test.
Statistically significant p-values are shown in black. Controls: n=9 and Hi/+:
n=4. Genotype of controls: Lo/+:n=4 ,Cre
+:n=3 ,a n d+/+:n=2 .Cre
+ animals
are wild type for Ctgf and +/+ animals are wild type for Ctgf and do not have a
Cre allele. BMD = bone mineral density and BMC = bone mineral content.
doi:10.1371/journal.pone.0012909.t001
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Ctgf is causal in fibrotic disease. In addition, by generating mouse
lines with varying Ctgf expression using the endogenous locus, the
function of Ctgf in fibrotic disease can be tested more effectively.
We note that this method of altering gene expression, through
altering a gene’s 39UTR, avoids many of the issues of random
insertion transgenes including insertional mutagenesis. Addition-
ally, a single founder with the Lo-Hi allele in combination with
existing resources allows the production of an allelic series of
quantitative variants. We also note that, the construct can be
arranged to produce a Hi-Lo allele which high expression allele
can be switched to low expression allele. Altogether, this method
will likely be particularly useful for genes with multiple separate
functions, genes expressed in many tissues, as well as in cases
where altered gene expression causes embryonic lethality.
Methods
Ethics statement
All animals were cared for in accordance with guidelines set
forth by the Association for Assessment and Accreditation of
Laboratory Animal Care. The University of North Carolina –
Chapel Hill’s ‘‘Institutional Animal Care and Use Committee’’
(IACUC) approved all studies (protocol #08-045 and #07-228).
Table 2. Strains in the Ctgf allelic series.
Ctgf genotype Allele
Ctgf mRNA
Expression
KO/KO del/del 0%
Lo/KO c-fos-39/del 30%
+/KO WT/del 50%
Lo/Lo c-fos-39/c-fos-39 60%
Lo/+ c-fos-39/WT 85%
+/+ (WT) WT/WT 100%
Hi/+ inducible bGH-39/WT 360%
Hi/+ embryos bGH-39/WT 930%
Ctgf expression levels are relative to WT. A single WT allele expresses 50%
(2650%=100%). Each copy of the Ctgf Lo allele expresses about 30% of WT
(Lo/+=30%+50%<85%). Each copy of the Ctgf Hi allele expresses about 300%
to 860% of WT. Abbreviations: KO is knockout, del is exon 3–5 deletion, and 39 is
39UTR.
doi:10.1371/journal.pone.0012909.t002
Figure 7. Ctgf mRNA levels in tamoxifen treated adults and CTGF protein abundance in plasma. A) Ctgf mRNA determined by RT-PCR in
tamoxifen treated mice from a cross of Ctgf Lo/Lo and CAG-Cre +/2 animals on a B6.129 F1 background. All animals were treated with tamoxifen and
Lo/+ is set to 85% as a control. Lo/+: n=23 and Hi/+: n=20. B) Quantification of CTGF protein abundance in plasma as calculated using ImageJ. Lo/Lo:
n=5,+/+: n=5, and Hi/+: n=7 animals for each genotype. C) A 330 bp band corresponds to the Ctgf Lo allele and a 240 bp band corresponds to the
Ctgf Hi allele. The PCR reaction is not quantitative but the presence of the 240 bp band indicates that Cre-mediated excision of DNA flanked by the
loxP sequences has taken place. Presence of 330 bp band in animals with Ctgf Hi allele (Hi) indicates that the excision is not complete. DNA from the
wild type animal (WT) does not amplify with these primers indicating the absence of the Ctgf Lo allele. The lane of size markers is indicated by M. D) A
representative western showing a doublet band for CTGF just above 31 kDa for three Ctgf Lo/Lo mice, three WT mice and three Ctgf Hi/+ mice. In A)
Lo/+ animals are heterozygous for the Ctgf Lo allele and do not have a Cre allele. In A), B), and D) Hi/+ animals are heterozygous for the Ctgf Hi allele,
have one tamoxifen-inducible CAG-Cre. All animals have been treated with tamoxifen.
doi:10.1371/journal.pone.0012909.g007
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In order to inactivate the Ctgf gene, we have made a targeting
construct to delete exons 3 through 5 of the Ctgf gene in the
genome in ES cells as illustrated in Fig. 1A. The 59 and 39 arms of
homology are a 4.7 kb BamH1/Nhe1 fragment and a 1.4 kb
Nsi1/Bgl2 fragment, respectively, and a neomycin resistant gene
(neo) was used as a selection marker. The Ctgf-Lo allele (Figure 1B)
was made by replacing the endogenous Ctgf gene 39UTR sequence
with a cassette that includes a loxP site, followed by the 39UTR
sequence from the c-Fos gene (c-Fos-39UTR), neo, a second lox P
site, and the 39UTR from the bovine growth hormone gene (bGH-
39UTR). A 1060 bp fragment of DNA including the Ctgf-39UTR
sequence, 510 bp of 39flanking and the polyA addition signal were
removed from the endogenous locus leaving the 20 bp immedi-
ately following the TAA stop codon intact.
Gene targeting in mouse ES cells (TC1) from 129S6/SvEvTac
(129/SvEv) was carried out using the procedures described
previously [27,51]. Cells with planned mutations were identified
with PCR, followed by confirmation with Southern blot analyses,
and used for generating mice carrying the mutations.
Mice
Both the Ctgf KO and Ctgf Lo-Hi mice were established and
maintained on a 129S6/SvEvTac (129/SvEv) background. The
Ctgf Lo-Hi mice were also backcrossed to C57BL6/J (B6) then
intercrossed two to three generations to create a mixed B6.129
background. Initial experiments were with these mixed back-
ground animals as noted.
The B6.FVB-TgN(EIIa-Cre)C5379Lmgd/J (EIIa-Cre) constitu-
tive global Cre expressing mice were a gift from Dr. Westphal at
the NIH [48]. The EIIa-Cre mice were backcrossed to 129/SvEv
mice for at least 18 generations before being bred to the Ctgf Lo-Hi
mice.
The inducible global Cre expressing mice are B6.Cg-Tg(CAG-
cre/Esr1)5Amc/J from The Jackson Laboratory, Bar Harbor, ME
stock number: 4682 (CAG-Cre) [28]. This Cre line uses the
chicken beta actin promoter/enhancer coupled with a cytomega-
lovirus enhancer (CAG) under control of a mutant mouse estrogen
receptor ligand binding domain. The latter receptor ligand
domain is unresponsive to estrogen but sensitive to the synthetic
ligand 4-hydroxytamoxifen (tamoxifen). Therefore, the CAG-Cre
allele produces robust expression of Cre only in the presence of
tamoxifen [28].
Genotyping
Animals were genotyped as appropriate using DNA from either
toe or tail snips using standard protocols. Ctgf KO animals were
genotyped by PCR with the primers: 59-TCG AGT TCA GAA
CCA GAG CT-39 (common), 59-TCC GAT TCC TAC CAG
GAA GT-39 (endogenous), and 59-TTA TGG CGC GCC ATC
GAT CT-39 (neo) with the conditions (92uC for 30 sec., 58uC for
30 sec, 60uC for 7 min) for 35 cycles. Because amplification is
passing through the highly repetitive 39UTR region the amplifi-
cation step is done at a lower temperature to improve Taq fidelity.
The endogenous band is 550 bp and the KO band is 320 bp.
Ctgf Lo alleles were genotyped by PCR with the primers: 59-
CAC TCT GCC AGT GGA GTT CA-39 (common), 59-TAA
TTT CCC TCC CCG GTT AC-39 (endogenous), and 59-CAC
AGC CTG GTG TGT TTC AC-39 (c-Fos) and the conditions
(92uC for 30 sec, 57uC for 45 sec, 65uC for 2.5 min) for 35 cycles.
The endogenous band is 525 bp and the Ctgf KO band is 375 bp.
Genotyping for Ctgf Hi allele was performed using fluorescent
primer probe sets in real time PCR with ABI 7500 Fast Real Time
PCR 3 system (Life Technologies Carlsbad, CA). The Ctgf Lo allele
was defined as the presence of the bGH-39UTR and neo and the
absence of Cre (where applicable). The Ctgf Hi allele was defined
as the presence of both the bGH-39UTR and Cre as well as a the
absence or low neo gene copy number. Primer sets for bGH-
39UTR: TGC CAG CCA TCT GTT GTT TG (forward), ACA
GTG GGA GTG GCA TCT T (reverse), and FTC TCC CCC
GTG CCT TCC TTG AQ (probe), for neo: GAC GGC GAG
GAT CTC GTC G (forward), TAT GTC CTG ATA GCG GTC
CG (reverse), and FAC CCA TGG CGA TGC CTG CTT GCC
GQ (probe), and for Cre: GGC AGT AAA AAC TAT CCA GCA
(forward), GCC GCA TAA CCA GTG AAA CA (reverse), FAT
TGC TGT CAC TTG GTC GTG GCA GCQ (probe). For all
probes F is 59 fluorescein (FAM) and Q is the 39 quencher
(TAMRA).
Quantitation of Neo gene copy number
When genotyping by real time PCR relative gene copy number
for the allele of interest, in this case the neo gene, is quantitatively
measured. We have used the relative neo gene copy number
information from RT-PCR genotyping as a proxy for determining
the efficiency of excision of the Lo (c-fos-39UTR and neo) portion
of the Ctgf Lo-Hi allele.
Embryo Recovery
To recover embryos, females were checked for mucosal plugs
every morning. If a plug was observed the female was separated
and watched for pregnancy by visual inspection. At the designated
embryonic day point (from E10 – E15 for these experiments)
mothers were sacrificed and embryos were recovered live. The
embryonic sac (amnion) was separated from each embryo and
used for genotyping. Each intact embryo was rinsed in PBS then
weighed whole (when possible) and assessed for phenotype. At
recovery, embryos were phenotypically classified based on body
weight and gross appearance before genotype was determined.
‘‘Normal’’ embryos were nondysmorphic in appearance and at the
expected developmental stage for the embryonic age and were
within two standard deviations (heavier or lighter) of the mean
embryo weight for that litter. ‘‘Small’’ embryos were nondys-
morphic in appearance and at the expected developmental stage
for the embryonic age, but were small in size and had a body
weight below two standard deviations of the litter average (litter
averages include all pups that are sufficiently intact to be weighed).
‘‘Small atypical’’ embryos were developmentally delayed, macer-
ated, or poorly vascularized and had a body weight below two
standard deviations of the litter average. Embryos were fixed with
4% paraformaldehyde or gluteraldehyde as needed for further
studies.
Ctgf Gene Expression Profiling
Mice were euthanized with an overdose of 2,2,2-tribromoeth-
anol and mRNA was harvested from tissues for gene expression
profiling. Assays were performed by real-time quantitative RT-
PCR as previously described [27]. The primer/probe sets used for
Ctgf mRNA expression were: AGT CGC CTC TGC ATG GTC
A (forward), GCG ATT TTA GGT GTC CGG AT (reverse), and
FCC TGC GAA GCT GAC CTG GAG GAA AQ (probe). All
samples were normalized to b-actin using primer set: AAG AGC
TAT AGA CTG CCT GA (forward), ACG GAT GTC AAC
GTC ACA CT (reverse), and FCA CTA TTG GCA ACG AGC
GGT TCC GQ (probe). Additional samples for gene expression
were either tail samples from 10–12 day old pups or whole
embryos harvested from timed matings at embryonic day E10-12
(days post-coitum). For tamoxifen treated animals, three weeks
after tamoxifen treatment ear tissue biopsies were taken by small
Ctgf Gene Expression Variants
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Immunohistochemistry
Embryos were recovered and sectioned as described above.
Sections were deparrafinned then stained with Rabbit anti-CTGF
primary antiboday at 1:100 or 1:500 dilution (Genetex Irvine, CA)
and a anti-Rabbit Alexa Fluor 594 at 1:200 dilution (Molecular
Probes Eugene, OR). Sections were counterstained with DAPI to
visualize nuclei. To correct for autofluorescence, for each section
there was an adjacent section stained with secondary antibody
only. Sections were examined on a Nikon Eclipse 80i and
photographned with Nikon DS-QiMc 12mp digital camera and
NIS Elements BR 3.0, SP6 (build 539) software.
Body mass composition and bone density
Using Dual Energy X-ray Absorptiometry (DEXA) we
measured body mass composition and bone density. Mice were
lightly anesthetized with isofluorane then scanned, excluding the
head, using PIXImus DEXA (Lunar Corporation, Madison, WI).
Measurements and calculations were performed as previously
described [52]. For analysis of DEXA data, males and females
were pooled and put in two groups, either Ctgf Hi/+ or controls
(including sibling controls of the genotypes Ctgf Lo/+;Cre-, Ctgf +/+;
Cre
+, or completely wild type).
Tamoxifen Treatment
The Ctgf Lo/Lo mice were crossed to the tamoxifen inducible
CAG-Cre mice to produce Ctgf Lo/+ and Ctgf Lo/+; Cre
+ mice. At
six weeks of age mice were treated with tamoxifen at a dose of
3 mg/kg of body weight for four consecutive days [28,53,54].
Following treatment the Ctgf Lo/+; Cre
+ mice are designated with
the genotype Ctgf Hi/+. Mice were monitored for any overt
phenotypic changes.
PCR Validation of Ctgf Lo-Hi allele
DNA was isolated from skin biopsy samples of animals that
carry a single copy of the modified allele and with or without
tamoxifen-inducible global Cre transgene. All animals were
treated with tamoxifen four months prior to the collection of the
samples. The Ctgf-Lo was allele amplified with primer1 (59-ACA
GGA AGA TGT ACG GAG AC-39, corresponding to the sense
strand of Ctgf exon 5) and primer2 (59-GCT ACA TCT CTG
GAA GAG GT-39, corresponding to the antisense strand of cFos
39UTR) and the Ctgf-Hi allele amplified with primer1 and primer3
(59-CAC CTA CTC AGA CAA TGC GA-39, corresponding to
the antisense strand of bGH 39UTR sequence. PCR products
were run on 1.5% agarose gel and stained with ethidium bromide
to visual bands.
Western Blot and Protein Quantitation of Plasma
All plasma samples for western blot and protein quantita-
tion were obtained through retro-orbital or tail vein bleed on
anesthetized mice. 0.5 M EDTA was added to whole blood it was
spun to obtain plasma. Plasma was used fresh or frozen at 220uC
until used. Pre-poured (Nu-Sep iGel) 10% polyacrylamide gels
were loaded with 1 mL of plasma mixed with loading buffer. Gels
were run, transferred and blotted by standard methods. Mem-
branes were blocked using 10% nonfat milk in tris-buffered saline
with Tween (TBST). Primary CTGF antibody (US Biological
Rabbit anti mouse-CTGF) was applied overnight 1:2000 dilution.
Secondary (Cal Biochem Goat anti-Rabbit IgG Peroxidase Conju-
gated) was applied for 3 hours 1:5000 dilution. Chemiluminescence
(Pierce Biotechnology SuperSignal West Pico Chemiluminescent
Substrate) was applied per manufacturer instructions. Band density
was quantitated with ImageJ software.
Microscopy/Photography
Adult mice were lightly anesthetized with 2,2,2-tribromoethanol
then photographed live (Canon Powershot SD600, Canon, NY,
USA). Whole fixed E13.5 embryos were pictured using a dissecting
macroscope (Leica Wild M420 Leica, NY) with a QImaging
camera (QImaging MicroPublisher MP3, Surrey, BC, Canada).
Whole unfixed E10.5 embryos were pictured with embryos
immersed in buffered saline using light microscopy (Olympus
America Inc., Melville, New York). Embryos were then fixed and
prepared for scanning electron microscopy (EM) as previously
described [55]. Briefly, embryos were fixed in 2.5% glutaraldehyde
in Sorenson’s buffer. Secondary fixation was performed in 2%
osmium tetroxide in Sorenson’s buffer [55]. Samples were
dehydrated in consecutive ethanol washes then dried. Specimens
were mounted on aluminum stubs with colloidal silver, sputter
coated, then viewed and photographed by scanning EM (Zeiss
Supra 25 field emission scanning electron microscope, Carl Zeiss,
Thornwood, NY, USA).
Statistics
Data are presented as mean 6 standard error of the mean and
p-values are from paired Student t-test performed in Microsoft
Excel. Additional statistics including Chi Squares were performed
by hand. Any p-value less than 0.05 was considered statistically
significant.
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